Nkarta, Inc. (NKTX)

Speculative clinical-stage biotech: strong liquidity (about $243M cash/restricted cash/investments at 2026-06-30, with management guiding runway into 2029 per SEC filings) but no revenue and heavy ongoing cash burn (FY2025 operating cash outflow about $89M; TTM free-cash-flow yield around −52%). Valuation can look inexpensive versus cash, yet the investment case is still highly dependent on clinical and regulatory milestones rather than operating fundamentals.

Near-term narrative is dominated by the Aug 10 Q2 results/corporate update (announced) that was received negatively, and the last ~14d media tone is near-flat to slightly negative around losses/estimate trims. The 30–90d baseline is too sparse for a reliable delta, and the legal/regulatory scan surfaced no active cases or regulator-confirmed investigations (no red-flag cap applied).

NKTX has improved on the short frame — price is back above the SMA20, SMA200, EMA9 and EMA21, and MACD has crossed above its signal — but price is still below the SMA50 and MACD remains below zero, so this reads as a rebound inside a still-repairing intermediate trend rather than a fully confirmed bullish trend.